This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Covaris And HORIBA Instruments Form Strategic Relationship

WOBURN, Mass., Feb. 13, 2013 /PRNewswire/ -- Covaris, Inc., the leader in focused acoustic technologies for the life sciences, is pleased to announce the establishment of a marketing alliance with HORIBA Instruments of Irvine, CA, which is the U.S. sales and marketing division of HORIBA Limited of Kyoto, Japan.  This alliance integrates the Covaris Adaptive Focused Acoustics (AFA) and the HORIBA particle sizing technologies into the world's first fully automated formulation preparation station with integrated Process Analytical Technology (PAT).

Under the arrangement, the Covaris FS-220 GMP system will be integrated with HORIBA's LA-950V2 platform, providing point-of-use particle size characterization.  This PAT system is ideal for formulation preparation from early animal studies through First-In-Human (FIH) testing.  With full 21 CFR Part 11 compliant software, the combined system offers a complete solution in cGLP/cGMP environments.

Carl Beckett, General Manager of Covaris Process Technologies, states that, "We are enthusiastic about this association.  This combined system will accelerate drug development by improving the quality of studies up to and including FIH testing.  Also, it reduces errors when handing off preparations between the Discovery and Development Research centers and the Contract Research Organizations (CRO) by allowing a completely automated and documented method development.  Additionally, as our clients scale to FIH and ultimately clinical processes, they need to ensure the methods in development are phase appropriate and based on scalable technologies."

According to Dr. Mike Pohl, Vice President of HORIBA's Scientific Division, "Our client base ranges from startups to the largest multinational Pharma and Biotech companies.  As a result of our entering into this relationship with Covaris, our clients gain access to the most advanced technology.  It's critical that the analytic and characterization capabilities keep pace with the formulation technology, through the entire discovery/development cycle."  Dr. Pohl notes that many pharmaceutical customers are located along the East Coast.  "The combination of our Edison, NJ headquarters plus the Woburn, MA location of Covaris, Inc.; gives HORIBA a strong one-two punch to support these customers.  The ability to automate the preparation of formulations, and then document the quality up front prior to a study, will now be readily accessible to our customers."

The HORIBA Group of worldwide companies provides an extensive array of instruments and systems for applications ranging from automotive R&D, process and environmental monitoring, in-vitro medical diagnostics, semiconductor manufacturing and metrology, to a broad range of scientific R&D and QC measurements. Proven quality and trustworthy performance have established widespread confidence in the HORIBA Brand.  

Covaris Process Technologies designs, develops, and markets systems based on patented Adaptive Focused Acoustic (AFA) technology.  The AFA process, based on shock wave physics, delivers controlled, precise, and accurate energy to biological and chemical samples.  The process is non-contact, isothermal, and rapid.  Leading pharmaceutical companies worldwide are using Covaris instruments for Formulation development, of nanosuspensions, liposomes, and nanoemulsions.

Information about Covaris Process Technologies is available at http://www.covarisinc.com Information about HORIBA Scientific is available at http://www.horiba.com/scientific

SOURCE Covaris, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs